---
title: "Guardant Health Unveils Promising Results from RADIOHEAD Study, Highlighting Early Detection of Immunotherapy Response in Advanced Cancer Patients"
description: "Guardant Health, Inc. has released promising results from the RADIOHEAD study, conducted in collaboration with the Parker Institute for Cancer Immunotherapy. The study, published in Cancer Research Co"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250593195.md"
published_at: "2025-07-29T12:07:15.000Z"
---

# Guardant Health Unveils Promising Results from RADIOHEAD Study, Highlighting Early Detection of Immunotherapy Response in Advanced Cancer Patients

> Guardant Health, Inc. has released promising results from the RADIOHEAD study, conducted in collaboration with the Parker Institute for Cancer Immunotherapy. The study, published in Cancer Research Communications, shows that Guardant Reveal, a tissue-free monitoring tool, can detect immunotherapy responses in advanced cancer patients up to five months earlier than traditional methods. Involving over 500 patients, the findings highlight the potential of blood-based monitoring to enhance treatment decision-making in cancer care.

Guardant Health, Inc. has announced the first clinical readout from their collaboration in the RADIOHEAD study with the Parker Institute for Cancer Immunotherapy. This study, results of which were published in Cancer Research Communications, evaluated the effectiveness of Guardant Reveal, a tissue-free monitoring tool, in detecting responses to immunotherapy across various solid tumor types in patients with advanced-stage cancer. The findings indicate that Guardant Reveal can identify non-responders to immunotherapy up to five months earlier than standard methods. The study involved over 500 patients and demonstrated a strong association between long-term patient outcomes and changes in tumor fraction measured through Guardant Reveal. These results underscore the potential of blood-based monitoring to improve treatment decision-making in cancer care. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250729660475) on July 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [GH.US - Guardant Health](https://longbridge.com/en/quote/GH.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Guardant Health (GH) Valuation Check After TRICARE Coverage Win For Shield Blood Test | Guardant Health (GH) has gained attention following TRICARE's decision to cover its Shield blood test for colorectal can | [Link](https://longbridge.com/en/news/272304771.md) |
| Guardant Health prelim Q4 revenue rises 39%, beats expectations | Guardant Health's preliminary Q4 revenue rose 39% to $280 million, surpassing analyst expectations of $267.82 million. T | [Link](https://longbridge.com/en/news/272220970.md) |
| Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results \| GH Stock News | Guardant Health, Inc. announced preliminary unaudited results for Q4 and full year 2025, reporting a 39% revenue growth  | [Link](https://longbridge.com/en/news/272189132.md) |
| Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families \| GH Stock News | Guardant Health's Shield blood test for colorectal cancer screening is now available for U.S. military members and their | [Link](https://longbridge.com/en/news/271937376.md) |
| Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 116 Shares of Stock | Guardant Health Director Musa Tariq sold 116 shares at $101.46 each, totaling $11,769.36, reducing his ownership by 1.43 | [Link](https://longbridge.com/en/news/270322342.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.